XD® Process - A revolution in process technology -- limited investment with huge impact

Pushing the cell density in mammalian systems to the max to drive yield improvements in the production of biopharmaceuticals.

DSM's XD^® Technology has been developed to drive yield improvements in the production of biopharmaceuticals. "XD" stands for eXtreme Density, as the process is able to push the cell density within the bioreactor to the max and thereby achieve maximum productivity. XD's ultrahigh yields allow for downsizing of bioreactors and opened avenues for new biopharmaceutical manufacturing concepts.

Would you like to increase your reactor output without changes to the genetic construct? 

DSM’s XD® Process offers the solution:

• 5-10 fold increase for your process
• Extending the capabilities of your fed-batch process/plant
• Achieve unmet yields e.g. 12 g/L for standard IgG based on CHO or 27 g/L for standard IgG based on PER.C6^® cell line

How it works
Keep the environment of your manufacturing cells constant and increase the cell density by consistent nutrient supply. At the end of the cultivation (14 days) the complete harvest will be processed as in any other fed-batch process. During cultivation the medium will be replenished based on the needs of the cells, while the cells and the product are retained in the reactor with a retention device.


PER.C6^® is a registered trademark of Crucell Holland B.V.
XD^® is a trademark of DSM N.V.